content_copy Anti-Aging Stem Cell Therapy Improves Quality of Life - Vitro Biopharma

Anti-Aging Stem Cell Therapy Improves Quality of Life

August 14, 2021

Anti-Aging Stem Cell Therapy Improves Quality of Life

October 31, 2017

Scientists at the University of Miami Miller School of Medicine completed a clinical trial showing safety and efficacy of stem cell therapy in treatment of frailty, a common aging symptom caused by reduced function of stem cells and inflammation.1 Stem cells in the body serve several functions including repair and regeneration of damaged tissues, production of 200 billion red blood cells per day and other healing processes.  As we age, stem cells become reduced in number & function.  The authors thus used adult stem cells (MSCs) administered by intravenous (IV) infusion allowing access to all tissues in the body. Stem cells migrate to regions of inflammation, where anti-inflammatory effects are mediated through secretion of various anti-inflammatory agents.  The procedure was found safe without adverse events.  Also, there were statistically significant improvements in physical performance and immune markers of frailty.  Another larger, multi-center trial is now under way.  This study provides support for reduction of frailty and inflammatory conditions in aging patients.  Quality of life is improved by reducing the risk of injury from falls, etc.  Stem cell therapy may also extend life through anti-aging effects (telomere lengthening, etc).  This trial did not address this issue.

Vitro Biopharma has a similar ongoing trial with comparable early results.  No adverse events have been observed and immunological markers of inflammation are reduced.  Also, quality of life metrics improved including overall well-being, increased energy and physical performance.  Stem cell therapies exert benefits by several mechanisms including the secretion of a variety of biological agents mediating immunomodulation, anti-inflammation and cellular protective effects.  Stem cells also differentiate into a variety of cells that can replace damaged or dead cells. In addition, stem cells form intercellular channels through tunneling nanotubes that transfer organelles such as mitochondrial resulting in an additional cellular repair mechanism of stem cell therapies. For information about enrollment in this trial, please contact Vitro Biopharma at (303)-999-2130.

By Jim Musick, Ph.D. CSO of Vitro Biopharma/Vitro Diagnostics, Inc.; Tiana Tonrey, MS, Laboratory Manager, Vitro Biopharma

References:

  1. Tompkins, BA, et al, Allogeneic Mesenchymal Stem Cells Ameliorate Aging Frailty: A Phase II Randomized, Double-blind, Placebo-Controlled Clinical Trial, J. Gerontol. A. Biol. Sci. Med Sci. 72: 1513-1521, 2017



Also in Blogs

Stem Cell Therapy of Stroke: Current Research Support and Clinical Studies
Stem Cell Therapy of Stroke: Current Research Support and Clinical Studies

August 14, 2021 0 Comments

Adult stem cell therapy is a common FDA-approved procedure for the treatment of blood disorders including leukemia, lymphoma and autoimmune diseases. Cell therapy using other types of adult stem cells including mesenchymal stem cells (MSCs), neural stem cells (NSCs) and muscle stem cells (Satellite cells).

Read More

Immunotherapy of Solid Tumor Cancers: Role of Cancer Associated Fibroblasts
Immunotherapy of Solid Tumor Cancers: Role of Cancer Associated Fibroblasts

August 14, 2021 0 Comments

Cancer therapy traditionally involves surgery, radiation or chemotherapy to kill cancer cells that are normal cells lacking control that limit growth. Cancer cells produce continually growing tumors that spread to other tissues, and eventually kill.

Read More

Recent Advances in Stem Cell Therapy of Stroke
Recent Advances in Stem Cell Therapy of Stroke

August 14, 2021 0 Comments

An interim report of a clinical trial of intracerebral injection of stem cells adds to a growing body of evidence supporting safety and efficacy of stem cell therapy for stroke.  A clinical team led by Dr. Gary Steinberg at Stanford University Medical Center reported results from 16 patients who received stereotactic injections into damaged brain regions consisting of MSCs that were modified to facilitate their differentiation into neural stem cells.

Read More